KYRNF.US KYORIN Pharmaceutical Co., Ltd.

Healthcare Drug Manufacturers - Specialty & Generic USA Stocks
10.31 USD
Close of Nov 14, 2026
10.17 10.31
Market cap
USD 592M
P/E
25.8x
P/B
0.67x
ROE
2.3%
Dividend yield
3.49%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is KYRNF.US undervalued?

Graham number
Price10.31
Graham value11.74
Discount12.2%

KYRNF.US trades 12.2% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KYORIN Pharmaceutical Co., Ltd. fundamental analysis

No fundamental analysis for KYORIN Pharmaceutical Co., Ltd. yet.

KYORIN Pharmaceutical Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KYORIN Pharmaceutical Co., Ltd.

KYORIN Pharmaceutical Co., Ltd., through its subsidiaries, researches and develops, manufactures, and sells generic drugs in Japan and internationally. The company is also involved in drug discovery and licensing activities. It also offers infectious disease-related products; over-the-counter drug; and generic drugs. The company was formerly known as KYORIN Holdings, Inc. KYORIN Pharmaceutical Co., Ltd. was founded in 1923 and is headquartered in Tokyo, Japan.

Full company profile